News

Fierce Biotech10h
Lilly's oral GLP-1 data 'as good as it gets' at 12% weight loss, exec says
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Verywell Health on MSN9h
Lilly’s Oral GLP-1 Drug Shows Modest Weight Loss Results Compared to Injectables
People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...
Eli Lilly beats earnings for second quarter on strong GLP-1 sales, stock dives on GLP-1 pill trial results
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.
Devdiscourse7h
Eli Lilly's GLP-1 Pill: A Diminished Competitor in the Obesity Drug Race
Eli Lilly's experimental GLP-1 pill showed a 12.4% body weight reduction, less than Novo Nordisk's injectable Wegovy in a ...
Eli Lilly raises 2025 revenue guidance to $60B-$62B while expanding GLP-1 pipeline and production
Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...
Fierce Pharma1d
Novo's outgoing CEO prepares to hand off business as sales threats from Lilly, GLP-1 compounders persist
On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...